Donner Elizabeth J, Snead O Carter
Division of Neurology and Program in Brain and Behavior, Hospital for Sick Children, Department of Pediatrics, Faculty of Medicine, University of Toronto, MSG 1X8 Toronto, Ontario, Canada.
NeuroRx. 2006 Apr;3(2):170-80. doi: 10.1016/j.nurx.2006.01.013.
In the last 12 years, 10 new anticonvulsants have been approved by the U.S. Food and Drug Administration and, as a result, the treatment options for children and adults with epilepsy have been expanded considerably. These new generation antiepileptic drugs offer equal efficacy with improved tolerability, pharmacokinetic properties, and side effect profiles compared with the traditional drugs. With many new medications available, the clinician treating children with epilepsy must be well versed in the application of these drugs to their patient population. This manuscript will review the indications, mechanism of action, pharmacokinetics, adverse effects, and dosing of the new generation of anticonvulsant medications.
在过去12年里，10种新型抗惊厥药物已获美国食品药品监督管理局批准，因此，癫痫患儿及成人的治疗选择得到了大幅扩展。与传统药物相比，这些新一代抗癫痫药物疗效相当，耐受性、药代动力学特性及副作用情况均有所改善。有了多种新药可供选择，治疗癫痫患儿的临床医生必须精通这些药物在其患者群体中的应用。本文将综述新一代抗惊厥药物的适应证、作用机制、药代动力学、不良反应及给药剂量。
